API | pegaspargase

pegaspargase (oncaspar) Report issue

Biological Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). Often it is used together with anthracycline, vincristine, and corticosteroids. Pegaspargase can be administered either via an intravenous infusion or a intramuscular injection. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
pegaspargase

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$2764.3580 - $3664.1900

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (124)

Research & Development (124)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (34)

Approved Indications (1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications - Clinical Trial Phases 1-4 (34)

Down Syndrome (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 4)

Hodgkin Disease (Phase 2)

Leukemia (Phase 3)

Leukemia, B-Cell (Phase 2)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 3)

Leukemia, T-Cell (Phase 2/Phase 3)

Lymphohistiocytosis, Hemophagocytic (Phase 4)

Lymphoma (Phase 3)

Lymphoma, Extranodal NK-T-Cell (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 4)

Medulloblastoma (Phase 4)

Mucositis (Phase 3)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 4)

Ovarian Neoplasms (Phase 2)

Pediatrics (Phase 1)

Peritoneal Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma ()

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Testicular Neoplasms (Phase 3)

Treatment Refusal (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 151
# of Trial Organizations: 124

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue